L
Leona Fields
Researcher at University of Pennsylvania
Publications - 14
Citations - 558
Leona Fields is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Alzheimer's Disease Neuroimaging Initiative & Transplantation. The author has an hindex of 10, co-authored 14 publications receiving 498 citations. Previous affiliations of Leona Fields include Hospital of the University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses.
Miroslaw Majewski,Magdalena Korecka,Joanne Joergensen,Leona Fields,Plamen Kossev,Walter Schuler,Leslie M. Shaw,Mariusz A. Wasik +7 more
TL;DR: Everolimus displays a potent inhibitory effect on PTLD-derived cells in vitro and in vivo in a dose range leading to prevention of allograft rejection and may prove effective in both the prevention and treatment of PTLDs in transplant patients.
Journal ArticleDOI
The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans
Ju-Hee Kang,Ju-Hee Kang,Magdalena Korecka,Michal J. Figurski,Jon B. Toledo,Kaj Blennow,Henrik Zetterberg,Henrik Zetterberg,Teresa Waligorska,Magdalena Brylska,Leona Fields,Nirali Shah,Holly Soares,Robert A. Dean,Hugo Vanderstichele,Ronald C. Petersen,Paul S. Aisen,Andrew J. Saykin,Michael W. Weiner,Michael W. Weiner,John Q. Trojanowski,Leslie M. Shaw +21 more
TL;DR: In this paper, the authors describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ 1-42 ), t-tau, and p-Tau 181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and increased risk for progression to AD; AD heterogeneity; progress in standardization; and new studies using ADNI biofluids.
Journal ArticleDOI
Factors influencing theophylline serum protein binding
TL;DR: The wide range of reported values for theophylline binding to serum proteins in normal and asthmatic adults at least partly results from differences in the conditions used for the separation of free from bound drug.
The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans
Ju-Hee Kang,Magdalena Korecka,Michal J. Figurski,Jon B. Toledo,Kaj Blennow,Henrik Zetterberg,Teresa Waligorska,Magdalena Brylska,Leona Fields,Nirali Shah,Holly Soares,Robert A. Dean,Hugo Vanderstichele,Ronald C. Petersen,Paul S. Aisen,Andrew J. Saykin,Michael W. Weiner,John Q. Trojanowski,Leslie M. Shaw,Alzheimer’s Disease Neuroimaging Initiative +19 more
TL;DR: Alzheimer's Disease Neuroimaging Initiative Biomarker Core progress including the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ1–42), t‐t Tau, and p‐tau181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and increased risk for progression to AD are described.
Journal ArticleDOI
Derivation of cutoffs for the Elecsys® amyloid β (1–42) assay in Alzheimer's disease
Leslie M. Shaw,Teresa Waligorska,Leona Fields,Magdalena Korecka,Michal J. Figurski,John Q. Trojanowski,Udo Eichenlaub,Simone Wahl,Marian Quan,Michael J. Pontecorvo,D. Richard Lachno,Jayne A. Talbot,Scott W. Andersen,Eric Siemers,Robert A. Dean +14 more
TL;DR: An Elecsys® Amyloid β (Aβ [1–42]) immunoassay cutoff for classification of patients with Alzheimer's disease was investigated.